Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase II Study of Multi-agent Low Dose Chemotherapy GAX-CI followed by Olaparib and Pembrolizumab in Patients with Metastatic Pancreatic Adenocarcinoma

Summary

The purpose of this phase II trial is to evaluate the safety and efficacy of maintenance olaparib and pembrolizumab following multi agent, low dose chemotherapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan in patients with untreated metastatic adenocarcinoma.

General Information

NCT#: NCT04753879
Study ID: J2112
Trial Phase: Phase II

Trial Sponsor: Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Capecitabine, Irinotecan, Cisplatin, Olaparib, Pembrolizumab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search